Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
REGENCELL BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
25.10. | Regencell Bioscience Holdings Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
23.07. | What Is Going on With Regencell Bioscience (RGC) Stock Today? | 8 | InvestorPlace | ||
20.06. | Regencell Bioscience Holdings Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BB BIOTECH | 39,300 | +1,68 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,949 | +2,59 % | Palatin Technologies Inc. Loss At -$7.82 Mln In Q1 | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced Loss for first quarter of -$7.82 millionThe company's earnings totaled -$7.82 million, or -$0.39 per share. This compares with... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Announces Closing of Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
GINKGO BIOWORKS | 6,900 | 0,00 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
BEAM THERAPEUTICS | 25,070 | +6,32 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
ONCOLYTICS BIOTECH | 0,915 | -3,17 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights | BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 16,920 | -0,88 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
ASSERTIO | 0,936 | -3,08 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
SIGA TECHNOLOGIES | 6,500 | +3,83 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
VIR BIOTECHNOLOGY | 7,120 | +2,45 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
VERVE THERAPEUTICS | 4,835 | +5,11 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
TRAVERE THERAPEUTICS | 17,900 | +1,70 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level |